Marksans Pharma Limited (MARKSANS.NS)
INR 314.2
(-1.83%)
INR 314.2
(-1.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.58 Billion INR | 15.04% |
| 2022 | 3.98 Billion INR | 35.33% |
| 2021 | 3 Billion INR | -16.88% |
| 2020 | 3.46 Billion INR | 87.69% |
| 2019 | 1.92 Billion INR | 42.18% |
| 2018 | 1.36 Billion INR | 59.76% |
| 2017 | 868.56 Million INR | 67.75% |
| 2016 | 329.19 Million INR | -64.92% |
| 2015 | 1.45 Billion INR | -21.83% |
| 2014 | 1.75 Billion INR | 53.39% |
| 2013 | 1.13 Billion INR | 67.62% |
| 2012 | 706.5 Million INR | 171.92% |
| 2011 | -997.4 Million INR | -1836.65% |
| 2010 | -913.68 Million INR | -119.7% |
| 2009 | 254.79 Million INR | -14.33% |
| 2008 | 297.14 Million INR | -28.25% |
| 2007 | 416.53 Million INR | 48.02% |
| 2006 | 281.57 Million INR | -38.22% |
| 2005 | 444.98 Million INR | 18.26% |
| 2004 | 379.46 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.28 Billion INR | 13.64% |
| 2023 Q2 | 1.32 Billion INR | 18.64% |
| 2023 Q3 | 1.37 Billion INR | 3.67% |
| 2023 Q1 | 1.12 Billion INR | -7.05% |
| 2023 FY | - INR | 15.04% |
| 2023 Q4 | 1.09 Billion INR | -20.45% |
| 2022 Q4 | 1.2 Billion INR | 27.85% |
| 2022 Q2 | 944.2 Million INR | 5.66% |
| 2022 FY | - INR | 35.33% |
| 2022 Q1 | 893.6 Million INR | 17.69% |
| 2022 Q3 | 942.96 Million INR | -0.13% |
| 2021 Q3 | 698.6 Million INR | 1.74% |
| 2021 Q1 | 832.21 Million INR | -14.09% |
| 2021 FY | - INR | -16.88% |
| 2021 Q2 | 686.65 Million INR | -17.49% |
| 2021 Q4 | 759.29 Million INR | 8.69% |
| 2020 Q3 | 878.91 Million INR | 1.23% |
| 2020 Q2 | 868.24 Million INR | 23.68% |
| 2020 Q1 | 702.03 Million INR | 7.26% |
| 2020 FY | - INR | 87.69% |
| 2020 Q4 | 968.68 Million INR | 10.21% |
| 2019 Q3 | 473.11 Million INR | 14.15% |
| 2019 Q1 | 345.96 Million INR | 59.81% |
| 2019 Q4 | 654.49 Million INR | 38.34% |
| 2019 Q2 | 414.48 Million INR | 19.81% |
| 2019 FY | - INR | 42.18% |
| 2018 Q4 | 216.48 Million INR | -40.43% |
| 2018 Q3 | 363.44 Million INR | 0.06% |
| 2018 Q2 | 363.24 Million INR | -6.18% |
| 2018 FY | - INR | 59.76% |
| 2018 Q1 | 387.18 Million INR | 14555.43% |
| 2017 FY | - INR | 67.75% |
| 2017 Q4 | 2.64 Million INR | -99.1% |
| 2017 Q3 | 292.37 Million INR | 18.89% |
| 2017 Q2 | 245.92 Million INR | -15.31% |
| 2017 Q1 | 290.38 Million INR | 385.13% |
| 2016 Q3 | 288.61 Million INR | 346.07% |
| 2016 Q2 | 64.7 Million INR | -21.75% |
| 2016 Q1 | 82.68 Million INR | 19.91% |
| 2016 Q4 | 59.85 Million INR | -79.26% |
| 2016 FY | - INR | -64.92% |
| 2015 Q2 | 513.81 Million INR | -1.96% |
| 2015 FY | - INR | -21.83% |
| 2015 Q3 | 305.82 Million INR | -40.48% |
| 2015 Q4 | 68.94 Million INR | -77.45% |
| 2015 Q1 | 524.07 Million INR | 51.9% |
| 2014 Q1 | 427.97 Million INR | 105.21% |
| 2014 Q4 | 345 Million INR | -34.24% |
| 2014 Q3 | 524.61 Million INR | 2.95% |
| 2014 FY | - INR | 53.39% |
| 2014 Q2 | 509.59 Million INR | 19.07% |
| 2013 Q4 | 208.55 Million INR | -41.27% |
| 2013 Q3 | 355.12 Million INR | 19.75% |
| 2013 Q1 | 264.57 Million INR | -31.19% |
| 2013 FY | - INR | 67.62% |
| 2013 Q2 | 296.55 Million INR | 12.09% |
| 2012 Q1 | -102.57 Million INR | 0.0% |
| 2012 FY | - INR | 171.92% |
| 2012 Q4 | 384.48 Million INR | 101.34% |
| 2012 Q3 | 190.96 Million INR | -16.97% |
| 2012 Q2 | 229.98 Million INR | 324.21% |
| 2011 FY | - INR | -1836.65% |
| 2010 FY | - INR | -119.7% |
| 2009 FY | - INR | -14.33% |
| 2008 FY | - INR | -28.25% |
| 2007 FY | - INR | 48.02% |
| 2006 FY | - INR | -38.22% |
| 2005 FY | - INR | 18.26% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott India Limited | 16.97 Billion INR | 72.99% |
| Cipla Limited | 67.19 Billion INR | 93.175% |
| Gland Pharma Limited | 13.33 Billion INR | 65.6% |
| GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | 48.318% |
| Kopran Limited | 744.13 Million INR | -516.254% |
| NGL Fine-Chem Limited | 678.68 Million INR | -575.684% |
| Pfizer Limited | 8.23 Billion INR | 44.333% |
| Sanofi India Limited | 8.86 Billion INR | 48.289% |
| SMS Pharmaceuticals Limited | 1.21 Billion INR | -278.741% |
| TTK Healthcare Limited | 999.34 Million INR | -358.878% |